Natco Pharma

Natco Pharma recorded a 23 percent decline in its second-quarter net profit, closing the period at Rs 517.9 crore. The setback reflects a combination of moderating export revenues, intensified competition in key markets, and pressure on certain high-margin product categories. While domestic operations delivered stable contributions, weaker demand in international geographies—particularly the U.S. generics segment—affected overall profitability.

In a significant move to enhance its global presence, Hyderabad-based Natco Pharma has announced plans to acquire a 36% equity stake in South Africa’s Adcock Ingram for approximately Rs. 1,887 crore (USD 226 million). This investment, structured through a combination of share purchases and open offers, underscores Natco’s commitment to expanding into high-growth emerging markets. The acquisition will strengthen Natco’s footprint across the African continent, diversify its revenue streams, and align with its long-term strategy of scaling operations beyond India.

Natco Pharma Ltd., a key player in India’s pharmaceutical landscape, has confirmed that the U.S. Food and Drug Administration (USFDA) has issued a Form 483 with seven observations following a comprehensive inspection of its Kothur facility near Hyderabad. The inspection, conducted between June 9 and June 19, 2025, scrutinized compliance with current Good Manufacturing Practices (cGMP). Natco has assured stakeholders that it will address the cited observations within the prescribed regulatory timeframe.